Growth is oxygen. But when it evaporates, the consequences can be extreme - ask anyone who bought Cisco in the Dot-Com Bubble (Nvidia?) or newer investors who lived through the 2020 to 2022 COVID cycle. The risks that can come from buying these assets is precisely why we started StockStory - to isolate the long-term winners from the losers so you can invest with confidence. Keeping that in mind, here is one growth stock expanding its competitive advantage and two climbing an uphill battle. Two Growth Stocks to Sell: SoundHound AI (SOUN) One-Year Revenue Growth: +101% Founded in 2005, SoundHound AI (NASDAQ:SOUN) develops independent voice artificial intelligence solutions that enable businesses across various industries to offer customized conversational experiences to consumers. Why Is SOUN Not Exciting? Sky-high servicing costs result in an inferior gross margin of 44.1% that must be offset through increased usage Operating margin fell by 39 percentage points over the last year as it prioritized growth over profits Cash-burning tendencies make us wonder if it can sustainably generate shareholder value At $9.55 per share, SoundHound AI trades at 25.4x forward price-to-sales. Check out our free in-depth research report to learn more about why SOUN doesn’t pass our bar. Corcept (CORT) One-Year Revenue Growth: +30.9% Focusing on the powerful stress hormone that affects everything from metabolism to immune function, Corcept Therapeutics (NASDAQ:CORT) develops and markets medications that modulate cortisol to treat endocrine disorders, cancer, and neurological diseases. Why Are We Hesitant About CORT? Revenue base of $685.4 million puts it at a disadvantage compared to larger competitors exhibiting economies of scale Expenses have increased as a percentage of revenue over the last five years as its adjusted operating margin fell by 16.2 percentage points 16.1 percentage point decline in its free cash flow margin over the last five years reflects the company’s increased investments to defend its market position Corcept is trading at $78.01 per share, or 39x forward P/E. Read our free research report to see why you should think twice about including CORT in your portfolio, it’s free. One Growth Stock to Watch: Option Care Health (OPCH) One-Year Revenue Growth: +17% With a nationwide network of 177 locations serving 43 states and a team of over 4,500 clinicians, Option Care Health (NASDAQ:OPCH) is the largest independent provider of home and alternate site infusion services, delivering medications and clinical support to patients across the United States. Story Continues Why Do We Like OPCH? Annual revenue growth of 15.3% over the last five years beat the sector average and underscores the unique value of its offerings Share buybacks catapulted its annual earnings per share growth to 66.4%, which outperformed its revenue gains over the last five years Free cash flow margin jumped by 3.3 percentage points over the last five years, giving the company more resources to pursue growth initiatives, repurchase shares, or pay dividends Option Care Health’s stock price of $31.41 implies a valuation ratio of 19x forward P/E. Is now the right time to buy? Find out in our full research report, it’s free. Stocks We Like Even More The market surged in 2024 and reached record highs after Donald Trump’s presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we’re homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver’s seat and build a durable portfolio by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free.
1 Growth Stock with All-Star Potential and 2 to Avoid
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...